|
Title
|
|
|
|
Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Creutzfeldt-Jakob disease (CJD) is a rare neurodegenerative disorder. Since the emergence of variant CID (vCJD) vigilance concerning the disease's incidence has increased and the interest in accurate in vivo diagnosis has augmented. So far, a large number of biomarkers has been investigated as aid in the differential diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) and vCJD. These include, among others, neuron-specific enolase (NSE), microtubuli associated protein Tau, S-100 beta, amyloid-beta (A beta(1-42)) and the 14-3-3 protein. Multiple studies have confirmed that CSF detection of 14-3-3 protein by Western blot was the best single biomarker for sCJD with an average sensitivity and specificity of 92%. Also, in genetic and iatrogenic CJD (iCJD) patients with an average disease duration of less than 1 year, 14-3-3 is the best differential biomarker. Unfortunately, the 14-3-3 protein has a lower sensitivity if the disease duration exceeds beyond I year in both sporadic CID and other CJD types (vCJD, and specific genetic or iatrogenic CJD types). (c) 2004 Elsevier B.V. All rights reserved. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Clinical neurology and neurosurgery / Netherlands Society of Neurology. - Assen, 1974, currens
|
|
|
Publication
|
|
|
|
Assen
:
Van Gorcum
,
2005
|
|
|
ISSN
|
|
|
|
0303-8467
[print]
1872-6968
[online]
|
|
|
DOI
|
|
|
|
10.1016/J.CLINEURO.2004.12.002
|
|
|
Volume/pages
|
|
|
|
107
:5
(2005)
, p. 355-360
|
|
|
ISI
|
|
|
|
000231112300001
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|